menu
Showcases Stock ranks

Stock in Focus: Supernus Pharm (SUPN)

-- Sunday, March 15, 2020, 11:16 --

Company Profile:

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Recent News:

The company reported fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively. Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively. For full year 2020, the Company estimates net product sales to range from $360 million to $390 million. Operating earnings to range from $70 million to $100 million.

On November 11, 2019, the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SPN-812 for the treatment of patients with attention deficit hyperactivity disorder (ADHD).

 

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

SUPN’s strengths can be seen in its strong profitability and robust solvency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 27.70 with positive bias. We rate Supernus Pharm (SUPN) a STRONG BUY.

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator